Carisma Therapeutics company info

What does Carisma Therapeutics do?
Carisma Therapeutics (NASDAQ:CARM) is a biotechnology company dedicated to the discovery and development of innovative therapies. With a focus on engineered macrophage-based treatments, Carisma is at the forefront of initiating groundbreaking approaches to combat cancer and other critical illnesses. The company's operations span from research and development in cell therapy platforms to advancing clinical studies aimed at unlocking new treatment pathways. By leveraging its unique CAR-Macrophage platform, Carisma aims to harness the power of the immune system, offering new hope for patients through targeted, immune-based therapies. The company's primary objective is to deliver transformative treatments that can significantly improve patient outcomes, steering the future of immunotherapy towards more effective and less invasive options.
Carisma Therapeutics company media
Company Snapshot

Is Carisma Therapeutics a public or private company?


How many people does Carisma Therapeutics employ?


What sector is Carisma Therapeutics in?

pie chart
Health Care

Where is the head office for Carisma Therapeutics?

location pin
Head Office
Massachusetts, United States

What year was Carisma Therapeutics founded?

founded flag
Year Founded
What does Carisma Therapeutics specialise in?
/Cancer Therapy /CAR-Macrophages /Immunotherapy Research /Biotechnology Industry /Clinical Development /T Cell Therapies

What are the products and/or services of Carisma Therapeutics?

Overview of Carisma Therapeutics offerings
Development of chimeric antigen receptor macrophage (CAR-M) therapy targeting HER2 overexpressing tumors.
Advancement of CAR-M therapies for solid tumors with a focus on safety and efficacy.
Research into novel engineered macrophages for enhanced phagocytosis and anti-tumor activity.
Collaborations with industry and academic partners to broaden the applicability of CAR-M technology across various cancer types.
Investment in proprietary manufacturing processes to streamline the production of CAR-M cells.
Engagement in preclinical studies to explore the potential of CAR-M therapies in treating other diseases beyond cancer.

Who is in the executive team of Carisma Therapeutics?

Carisma Therapeutics leadership team
  • Mr. Steven  Kelly
    Mr. Steven Kelly
    President, CEO & Director
  • Mr. Michael  Klichinsky Ph.D., Pharm.D., PharmD
    Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD
    Co-Founder & Chief Scientific Officer
  • Mr. Richard S. Morris CPA
    Mr. Richard S. Morris CPA
    CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off.
  • Mr. Saar  Gill M.D., Ph.D.
    Mr. Saar Gill M.D., Ph.D.
  • Dr. Daniel J. Cushing FCP, Ph.D.
    Dr. Daniel J. Cushing FCP, Ph.D.
    Chief Technology & Development Officer
  • Mr. Eric H. Siegel J.D., MBA
    Mr. Eric H. Siegel J.D., MBA
    General Counsel & Corporate Secretary
  • Ms. Terry  Shields
    Ms. Terry Shields
    Senior Vice President of Human Resources
  • Mr. Tom  Wilton
    Mr. Tom Wilton
    Chief Business Officer